Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eton Pharmaceuticals (ETON) EBIT Margin (2019 - 2025)

Historic EBIT Margin for Eton Pharmaceuticals (ETON) over the last 7 years, with Q3 2025 value amounting to 6.07%.

  • Eton Pharmaceuticals' EBIT Margin fell 110000.0% to 6.07% in Q3 2025 from the same period last year, while for Sep 2025 it was 4.89%, marking a year-over-year increase of 42400.0%. This contributed to the annual value of 6.66% for FY2024, which is 28900.0% down from last year.
  • According to the latest figures from Q3 2025, Eton Pharmaceuticals' EBIT Margin is 6.07%, which was down 110000.0% from 7.79% recorded in Q2 2025.
  • In the past 5 years, Eton Pharmaceuticals' EBIT Margin ranged from a high of 45.08% in Q1 2021 and a low of 754.45% during Q3 2021
  • Its 5-year average for EBIT Margin is 63.36%, with a median of 7.8% in 2023.
  • Within the past 5 years, the most significant YoY rise in Eton Pharmaceuticals' EBIT Margin was 226141900bps (2021), while the steepest drop was 2000000000bps (2021).
  • Quarter analysis of 5 years shows Eton Pharmaceuticals' EBIT Margin stood at 21.57% in 2021, then crashed by -42bps to 12.5% in 2022, then crashed by -154bps to 6.69% in 2023, then soared by 181bps to 5.4% in 2024, then tumbled by -212bps to 6.07% in 2025.
  • Its EBIT Margin was 6.07% in Q3 2025, compared to 7.79% in Q2 2025 and 26.32% in Q1 2025.